Akebia Therapeutics Q4 2023 Earnings Report

Akebia Therapeutics EPS Results

• Actual EPS: -$0.04
• Consensus EPS: -$0.04
• Beat/Miss: Met Expectations
• One Year Ago EPS: -$0.04

Akebia Therapeutics Revenue Results

• Actual Revenue: $56.20 million
• Expected Revenue: $55.64 million
• Beat/Miss: Beat by +$560.00 thousand
• YoY Revenue Growth: N/A

Akebia Therapeutics Announcement Details

• Quarter: Q4 2023
• Date: 3/14/2024
• Time: Q4 2023 Earnings Release

Akebia Therapeutics (NASDAQ:AKBA), a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.